Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban


Aslan A. N. , Sari C., Bastug S., Sari S. O. , AKÇAY M. , DURMAZ T. , et al.

BLOOD COAGULATION & FIBRINOLYSIS, cilt.27, ss.226-227, 2016 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 27 Konu: 2
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1097/mbc.0000000000000442
  • Dergi Adı: BLOOD COAGULATION & FIBRINOLYSIS
  • Sayfa Sayısı: ss.226-227

Özet

Rivaroxaban, a highly selective direct factor Xa inhibitor, is a new oral anticoagulant approved by the US Food and Drug Administration in November 2011 for stroke prophylaxis in patients with nonvalvular atrial fibrillation. Because of its efficacy and once-a-day dosing, it is commonly preferred in patients with nonvalvular atrial fibrillation and intolerance to warfarin in clinical practice. However, it can result in some adverse effects such as bleeding, rashes and liver injury. Here, we described a very rare adverse reaction of rivaroxaban, jaundice due to intrahepatic cholestasis, appeared in a 71-year-old male patient after taking rivaroxaban. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.